Publications by authors named "A K Litvinov"

Introduction The use of antibiotics such as oral clindamycin has been effective in treating bacterial infections. However, this medication often comes with significant side effects, particularly those affecting the gastrointestinal (GI) system. This study aims to evaluate the impact of different doses of clindamycin on GI health, specifically examining side effects like stomach upset, diarrhea duration, stomach pain, and recovery time.

View Article and Find Full Text PDF

Background Emerging research suggests a correlation between poor oral health and cardiovascular diseases (CVDs), with inflammation being a central mechanism. Periodontitis and gingivitis are chronic inflammatory diseases that can lead to systemic health issues if untreated. It has been indicated previously that endodontic infections and missing teeth may contribute to elevated cardiovascular risk, and smoking exacerbates both periodontal and cardiovascular conditions.

View Article and Find Full Text PDF

Supersolids are states of matter that spontaneously break two continuous symmetries: translational invariance owing to the appearance of a crystal structure and phase invariance owing to phase locking of single-particle wavefunctions, responsible for superfluid phenomena. Although originally predicted to be present in solid helium, ultracold quantum gases provided a first platform to observe supersolids, with particular success coming from dipolar atoms. Phase locking in dipolar supersolids has been investigated through, for example, measurements of the phase coherence and gapless Goldstone modes, but quantized vortices, a hydrodynamic fingerprint of superfluidity, have not yet been observed.

View Article and Find Full Text PDF

PSonyx is a newly isolated phage that infects . This siphovirus was isolated from a French pond in the south of Paris by students from Paris-Saclay University. Its 80,277-bp singleton genome carries 136 protein-coding genes and 5 tRNAs.

View Article and Find Full Text PDF

Aim: To evaluate the clinical efficacy and safety of antiviral drug riamilovir in patients with acute respiratory viral infections (ARVI) of non-coronavirus (SARS-CoV-2) etiology with different dosing regimens.

Materials And Methods: The study included 150 patients with ARVI aged 18-27 years (50 patients received riamilovir in the regimen of 250 mg 3 times a day for 5 days, 50 patients received riamilovir in the regimen of 250 mg 5 times a day for 5 days, 50 patients received only pathogenetic treatment).

Results: The use of riamilovir in both treatment regimens led to a reduction in the duration of inpatient treatment.

View Article and Find Full Text PDF